Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The CNS AE of Lorlatinib in Patients with ALK-positive Advanced NSCLC

NCT06652555 is registered in ClinicalTrials.gov with Shanghai Pulmonary Hospital, Shanghai, China as lead sponsor.

NCT NCT06652555
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06652555 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The CNS AE of Lorlatinib in Patients with ALK-positive Advanced NSCLC
Lead sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Phase
Observational
Overall status
Not yet recruiting
Start date
October 30, 2024
Completion date
September 29, 2027
Enrollment
100 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

alk, nsclc